Payment overview · 2025
General Payments
$1,212.30
59 reported records · 18 companies
Healthcare provider profile · identity verified
John R Born, DO
Allopathic & Osteopathic Physicians|Family Medicine · WHEATON, IL · NPI 1225063357
Verified facts
What the public records show
CMS Open Payments records show John R Born, DO received $1,212.30 in general payments during 2025 across 59 reported records.
ABBVIE INC. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Synthroid, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $211.61 | 17.5% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $144.01 | 11.9% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $130.02 | 10.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $118.21 | 9.8% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $115.21 | 9.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.50 | 7.4% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $74.16 | 6.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.64 | 4.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.70 | 4.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $40.74 | 3.4% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $32.39 | 2.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.29 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.93 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.14 | 2.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.05 | 2.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.45 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.76 | 1.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.49 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,212.30 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $209.49 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $130.25 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $130.02 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $125.40 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $125.40 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $89.50 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $80.64 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $74.16 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $56.64 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.88 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $53.88 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $49.78 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.55 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $40.74 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.57 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $32.39 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 13 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 292 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
292 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
292 | 38 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 739 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 657 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 607 | 62 |
| Furosemide | Furosemide | 581 | 44 |
| Donepezil Hcl | Donepezil Hcl | 424 | 20 |
| Sertraline Hcl | Sertraline Hcl | 391 | 22 |
| Memantine Hcl | Memantine Hcl | 387 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 358 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 344 | 31 |
| Losartan Potassium | Losartan Potassium | 342 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 341 | 20 |
| Gabapentin | Gabapentin | 310 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 310 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 301 | 44 |
| Omeprazole | Omeprazole | 295 | 39 |
| Eliquis | Apixaban | 292 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 252 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 238 | 11 |
| Potassium Chloride | Potassium Chloride | 225 | 30 |
| Famotidine | Famotidine | 223 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 24 |
| Simvastatin | Simvastatin | 210 | 19 |
| Finasteride | Finasteride | 207 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 206 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 27 |
| Mirtazapine | Mirtazapine | 165 | 20 |
| Klor-Con M20 | Potassium Chloride | 163 | 13 |
| Lisinopril | Lisinopril | 158 | 30 |
| Myrbetriq | Mirabegron | 155 | suppressed |
| Risperidone | Risperidone | 148 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 138 | suppressed |
| Spironolactone | Spironolactone | 137 | 14 |
| Bumetanide | Bumetanide | 131 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 11 |
| Metformin Hcl | Metformin Hcl | 122 | 17 |
| Alendronate Sodium | Alendronate Sodium | 111 | suppressed |
| Carvedilol | Carvedilol | 111 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 109 | 17 |
| Januvia | Sitagliptin Phosphate | 103 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 18 |
| Trazodone Hcl | Trazodone Hcl | 89 | 15 |
| Cephalexin | Cephalexin | 87 | 60 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 86 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | suppressed |
| Tradjenta | Linagliptin | 78 | suppressed |
| Allopurinol | Allopurinol | 69 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 67 | suppressed |
| Jardiance | Empagliflozin | 67 | suppressed |
| Bupropion Xl | Bupropion Hcl | 65 | suppressed |
| Ezetimibe | Ezetimibe | 63 | 21 |
| Atenolol | Atenolol | 60 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 60 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 59 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 17 |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Mupirocin | Mupirocin | 57 | 48 |
| Methenamine Hippurate | Methenamine Hippurate | 56 | suppressed |
| Ibuprofen | Ibuprofen | 55 | suppressed |
| Latanoprost | Latanoprost | 54 | 12 |
| Jantoven | Warfarin Sodium | 53 | suppressed |
| Telmisartan | Telmisartan | 53 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 52 | suppressed |
| Fenofibrate | Fenofibrate | 51 | suppressed |
| Alprazolam | Alprazolam | 50 | 11 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 43 | suppressed |
| Haloperidol | Haloperidol | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 12 |
| Prednisone | Prednisone | 41 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 13 |
| Azithromycin | Azithromycin | 37 | 28 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 11 |
| Glipizide | Glipizide | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Dofetilide | Dofetilide | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Nystatin | Nystatin | 18 | 11 |
| Ondansetron Odt | Ondansetron | 18 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Naloxone Hcl | Naloxone Hcl | 14 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,212.30 · 59 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KISUNLA, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, SYNTHROID, TRELEGY ELLIPTA, TRINTELLIX, Tymlos, UBRELVY, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error